DOCSLIB.ORG

Antidepressant Effects of a Single Dose of Ayahuasca in Patients with Recurrent Depression: a Preliminary Report Fla´Via De L

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antidepressant Effects of a Single Dose of Ayahuasca in Patients with Recurrent Depression: a Preliminary Report Fla´Via De L Revista Brasileira de Psiquiatria. 2015;37:13–20 ß 2015 Associac¸a˜ o Brasileira de Psiquiatria doi:10.1590/1516-4446-2014-1496 ORIGINAL ARTICLE Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report Fla´via de L. Oso´rio,1,2 Rafael F. Sanches,1,3 Ligia R. Macedo,1 Rafael G. dos Santos,1 Joa˜o P. Maia-de-Oliveira,4 Lauro Wichert-Ana,1 Draulio B. de Araujo,5,6 Jordi Riba,3,7,8,9 Jose´ A. Crippa,1,2 Jaime E. Hallak1,2 1Department of Neurosciences and Behavior, Ribeira˜o Preto Medical School, Universidade de Sa˜o Paulo (USP), Ribeira˜o Preto, SP, Brazil. 2National Science and Technology Institute for Translational Medicine (INCT-TM), Brazil. 3Centre d’Investigacio´ de Medicaments, Servei de Farmacologia Clı´nica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 4Department of Clinical Medicine, Universidade Federal do Rio Grande do Norte (UFRN), Natal, RN, Brazil. 5Hospital Universita´rio Onofre Lopes, UFRN, Natal, RN, Brazil. 6Brain Institute, UFRN, Natal, RN, Brazil. 7Human Experimental Neuropsychopharmacology, Institut de Recerca, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 8Department of Pharmacology and Treatment, Universitat Auto`noma de Barcelona, Spain. 9Centro de Investigacio´n Biome´dica en Red de Salud Mental, CIBERSAM, Barcelona, Spain. Objectives: Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore have antidepressant actions. This study sought to evaluate the effects of a single dose of AYA in six volunteers with a current depressive episode. Methods: Open-label trial conducted in an inpatient psychiatric unit. Results: Statistically significant reductions of up to 82% in depressive scores were observed between baseline and 1, 7, and 21 days after AYA administration, as measured on the Hamilton Rating Scale for Depression (HAM-D), the Montgomery-A˚ sberg Depression Rating Scale (MADRS), and the Anxious-Depression subscale of the Brief Psychiatric Rating Scale (BPRS). AYA administration resulted in nonsignificant changes in Young Mania Rating Scale (YMRS) scores and in the thinking disorder subscale of the BPRS, suggesting that AYA does not induce episodes of mania and/or hypomania in patients with mood disorders and that modifications in thought content, which could indicate psychedelic effects, are not essential for mood improvement. Conclusions: These results suggest that AYA has fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder. Keywords: Psychedelic agents; dimethyltryptamine; harmine; monoamine oxidase inhibitors; therapeutic use Introduction low response rates, as well as adverse effects and latency to onset of therapeutic action.3 Thus, new Depression is a highly prevalent disorder and is associated interventions, particularly those that with the potential with intense personal suffering, increased mortality, and for acute effect, would have a huge impact on the 1,2 high morbidity. Although its etiology is unknown, some treatment of depression. The N-methyl-D-aspartate 3 theories suggest that biological factors may be implicated. (NMDA) receptor antagonist ketamine, for example, has One such theory is the monoamine hypothesis, which rapid and potent antidepressant effects in treatment- suggests that an imbalance in cerebral monoamines such resistant major depressive disorder (MDD) and bipolar as dopamine, norepinephrine, and, especially, serotonin is depression, and its use is considered one of the most 3 responsible for depressive symptomatology. The mono- exciting areas in contemporary psychiatric research.4,5 amine hypothesis is the theory on which the leading Ayahuasca (AYA), a botanical hallucinogen tradition- 3 commercially available antidepressants are based. ally used by indigenous groups of the Northwest Amazon Currently available treatments have limitations that can region for ritual and medicinal purposes,6,7 is a potential lead to low therapeutic effectiveness, especially related to candidate for this new generation of antidepressant research focusing on new pharmacological treatments that produce immediate and more pronounced effects. Correspondence: Jaime E. C. Hallak, Departamento de Neurocieˆncias AYA is prepared by prolonged decoction of the bark of the e Cieˆncias do Comportamento, Faculdade de Medicina de Ribeira˜o vine Banisteriopsis caapi with the leaves of the shrub 6 Preto, Universidade de Sa˜o Paulo, Hospital das Clı´nicas, 3 andar, 6,7 b Av. Bandeirantes, 3900, Ribeira˜o Preto, SP, Brazil. Psychotria viridis. B. caapi contains the -carboline E-mail: [email protected] alkaloids harmine, tetrahydroharmine (THH), and harma- Submitted Jun 20 2014, accepted Aug 08 2014. line, which act as monoamine oxidase A inhibitors 14 FL Oso´rio et al. (MAOI), while P. viridis is rich in the psychedelic antidepressants/substance use were considered exclu- tryptamine N, N-dimethyltryptamine (DMT).6,8-11 sion criteria. The psychoactive effects of AYA are produced by a The study was conducted in accordance with the combined action of peripheral (gastrointestinal and liver) Declarations of Helsinki and Tokyo concerning human monoamine oxidase A (MAO-A) inhibition by harmine and subject research and approved by the Research Ethics central 5-HT1A/2A/2C agonist action of DMT on frontal and Committee of Hospital das Clı´nicas da Faculdade de paralimbic brain areas.8,9,12 Studies conducted among Medicina de Ribeira˜o Preto da Universidade de Sa˜o long-term (i.e., years or decades) members of religious Paulo, Ribeira˜o Preto, state of Sa˜o Paulo, Brazil (HC-RP groups that use AYA ritually suggest that this population process no. 2484/2008). The volunteers received detailed does not present evidence of psychological, neuropsy- information on the nature of AYA, the general psycholo- chological, or psychiatric harm caused by AYA.13-15 In gical effects of hallucinogens, and its possible adverse fact, there are several reports describing reduced mental effects, as reported in the psychiatric literature. All volunteers health problems in AYA users.13-15 Nevertheless, given gave their written informed consent to participate. the small number of studies, most with a limited number of participants, there is insufficient information to allow a Drug definitive conclusion on this topic, and more studies on the potential long-term toxicity of AYA are required. We obtained a standard sample of AYA prepared by An increasing number of studies report antidepressive members of the Santo Daime community, consisting of the potential for AYA alkaloids in animals.16-24 Furthermore, stalks of B. caapi (rich in harmine, THH, and harmaline) a double-blind, placebo-controlled animal study reported combined with the washed leaves of P. viridis (rich in reduced hopelessness and panic-related signs after DMT), boiled and concentrated for several hours. The acute AYA administration,25 and preliminary data in resulting brew was stored in plastic bottles at room humans also support an antidepressive action for AYA.26 temperature at the Santo Daime community and sub- The agonist action of AYA alkaloids on serotonergic sequently in a refrigerator in the Department of receptors and its inhibitory effects on MAO-A, associated Neurosciences and Behavior, Ribeira˜o Preto Medical with field and laboratory evidence suggesting that AYA School, Universidade de Sa˜o Paulo, Ribeira˜o Preto, causes a sensation of well-being, led to the hypothesis Brazil. AYA was stored under refrigeration until the day that this substance could be useful in the treatment of of the experimental session. All AYA used in the present depression in humans. Thus, the objective of the present study was from this original batch. preliminary, open-label study was to evaluate the acute Each subject drank 120-200 mL of AYA (2.2 mL/kg effects of a single dose of AYA in patients diagnosed with body weight). The AYA batch used in the experiment depression and to test whether AYA administration could contained 0.8 mg/mL DMT, 0.21 mg/mL harmine, and no produce an acute antidepressant effect. harmaline at the chromatography detection threshold of 0.02 mg/mL. To quantify the content of each alkaloid, a 1-mL sample of AYA was homogenized with sodium Methods acetate buffer solution (pH = 9), extracted with 5 mL Volunteers diethyl ether in a shaker (20 min), and centrifuged at 3,000 rpm for 15 min. The organic phase was collected Six volunteers (two men and four women, mean age and evaporated under a nitrogen stream. The residue 44.16613.55 years) with a diagnosis of recurrent MDD was dissolved in 1 mL methanol and 1 mL of the resulting participated in the study. Within this group, two volunteers solution was analyzed by gas chromatography/mass were experiencing a current mild depressive episode, spectrometry (GC/MS), performed using a Varian three were experiencing a moderate episode, and one CP3800 gas chromatograph coupled to a Varian Saturn was experiencing a severe depressive episode. None of 2000 ion trap mass spectrometer (Varian Inc.). A capillary the volunteers were experiencing depressive episodes column (DB-5MS, 30 m 6 0.25 mm i.d. 6 0.25 mm film with psychotic symptoms. thickness; Agilent) was used. The chromatographic Participants were recruited through local advertise- conditions were as follows: injector temperature 2506C ments and by referrals from private psychiatric clinics. in splitless mode and oven temperature program
Load more

Recommended publications
  • Ayahuasca: Spiritual Pharmacology & Drug Interactions
    Ayahuasca: Spiritual Pharmacology & Drug Interactions BENJAMIN MALCOLM, PHARMD, MPH [email protected] MARCH 28 TH 2017 AWARE PROJECT Can Science be Spiritual? “Science is not only compatible with spirituality; it is a profound source of spirituality. When we recognize our place in an immensity of light years and in the passage of ages, when we grasp the intricacy, beauty and subtlety of life, then that soaring feeling, that sense of elation and humility combined, is surely spiritual. The notion that science and spirituality are somehow mutually exclusive does a disservice to both.” – Carl Sagan Disclosures & Disclaimers No conflicts of interest to disclose – I don’t get paid by pharma and have no potential to profit directly from ayahuasca This presentation is for information purposes only, none of the information presented should be used in replacement of medical advice or be considered medical advice This presentation is not an endorsement of illicit activity Presentation Outline & Objectives Describe what is known regarding ayahuasca’s pharmacology Outline adverse food and drug combinations with ayahuasca as well as strategies for risk management Provide an overview of spiritual pharmacology and current clinical data supporting potential of ayahuasca for treatment of mental illness Pharmacology Terms Drug ◦ Term used synonymously with substance or medicine in this presentation and in pharmacology ◦ No offense intended if I call your medicine or madre a drug! Bioavailability ◦ The amount of a drug that enters the body and is able to have an active effect ◦ Route specific: bioavailability is different between oral, intranasal, inhalation (smoked), and injected routes of administration (IV, IM, SC) Half-life (T ½) ◦ The amount of time it takes the body to metabolize/eliminate 50% of a drug ◦ E.g.
    [Show full text]
  • Basic Hypothesis and Therapeutics Targets of Depression: a Review
    ISSN: 2641-1911 DOI: 10.33552/ANN.2021.10.000738 Archives in Neurology & Neuroscience Review Article Copyright © All rights are reserved by Anil Kumar Basic Hypothesis and Therapeutics Targets of Depression: A Review Monika Kadian, Hemprabha Tainguriya, Nitin Rawat, Varnika Chib, Jeslin Johnson and Anil Kumar* Pharmacology Division, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandigarh 160014, India *Corresponding author: Dr. Anil Kumar, PhD, Professor of Pharmacology, Phar- Received Date: May 11, 2021 macology division, University Institute of Pharmaceutical Sciences, Panjab Univer- sity, Chandigarh 160014, India. Published Date: June 07, 2021 Abstract Depression is a psychological disorder marked by emotional symptoms such as melancholy, anhedonia, distress mood, loss of interest in daily life activities, feeling of worthlessness, sleep disturbances and destructive tendencies. According to WHO, more than 264 million people from all randomage groups processes are suffering during with brain depression development. thus, Depression it is become is mainlya leading due cause to neurotransmitter of disability and imbalances, infirmity worldwide. HPA disturbances, It is estimated increased that oxidative 40% of riskand nitrosativefor depression damage, is genetic impairment and the in other glucose 60% metabolism, is non-genetic and whichmitochondrial involved dysfunction, acute & chronic etc. The stress, monoamine childhood hypothesis trauma, viral is based infections on attenuation and even of monoamines such as serotonin (5-HT), norepinephrine (NE) and dopamine (DA) in the brain regions (hippocampus, limbic system and frontal cortex) that can cause depression like symptoms. Depression is also marked by increased level of corticotrophin-releasing hormone (CRH) and and impaired responsiveness to glucocorticoid hormone.
    [Show full text]
  • Preparation for a Workshop How to Prepare for Healing
    Preparation for a Workshop How to Prepare for Healing with Ayahuasca The Temple of the Way of Light http://templeofthewayoflight.org/ How to Prepare for Healing with Ayahuasca 2 Why Preparation is Important Comprehensive preparation for working with ayahuasca and a resolute commitment to ongoing integration after your retreat are as important as the healing you will experience whilst at the Temple. It is critical that you commit at the deepest level possible to the advice contained in this document – before, during and after your retreat – in order to ensure your healing experience is positive, safe and sustained over the long term. M any people from the West who are new to ayahuasca come with a misconception of the way the medicine works. There is no “quick fix” when awakening to higher aspects of consciousness or alleviating long-term pain and suffering. We can never offer any guarantees regarding healing, but we do sincerely and wholeheartedly promise to always try our best. Indigenous traditions have worked with ayahuasca for thousands of years and have never viewed it as a quick fix or a recreational experience. However, ayahuasca and the healing traditions of the Amazon are often able to offer a significant intervention into chronic emotional/psycho-spiritual imbalances and, sometimes, physical health conditions. It is fundamentally a transformational pathway to integrate and release the causes of pain and suffering. Ayahuasca is a powerful cleansing and purifying medicine that can rid the body of physical impurities, the mind and body of emotional blockages and self-limiting fear-filled patterns that have accumulated over a lifetime, as well as retrieve fragmented aspects of one’s soul due to past traumatic events.
    [Show full text]
  • Hallucinogens and Dissociative Drugs
    Long-Term Effects of Hallucinogens See page 5. from the director: Research Report Series Hallucinogens and dissociative drugs — which have street names like acid, angel dust, and vitamin K — distort the way a user perceives time, motion, colors, sounds, and self. These drugs can disrupt a person’s ability to think and communicate rationally, or even to recognize reality, sometimes resulting in bizarre or dangerous behavior. Hallucinogens such as LSD, psilocybin, peyote, DMT, and ayahuasca cause HALLUCINOGENS AND emotions to swing wildly and real-world sensations to appear unreal, sometimes frightening. Dissociative drugs like PCP, DISSOCIATIVE DRUGS ketamine, dextromethorphan, and Salvia divinorum may make a user feel out of Including LSD, Psilocybin, Peyote, DMT, Ayahuasca, control and disconnected from their body PCP, Ketamine, Dextromethorphan, and Salvia and environment. In addition to their short-term effects What Are on perception and mood, hallucinogenic Hallucinogens and drugs are associated with psychotic- like episodes that can occur long after Dissociative Drugs? a person has taken the drug, and dissociative drugs can cause respiratory allucinogens are a class of drugs that cause hallucinations—profound distortions depression, heart rate abnormalities, and in a person’s perceptions of reality. Hallucinogens can be found in some plants and a withdrawal syndrome. The good news is mushrooms (or their extracts) or can be man-made, and they are commonly divided that use of hallucinogenic and dissociative Hinto two broad categories: classic hallucinogens (such as LSD) and dissociative drugs (such drugs among U.S. high school students, as PCP). When under the influence of either type of drug, people often report rapid, intense in general, has remained relatively low in emotional swings and seeing images, hearing sounds, and feeling sensations that seem real recent years.
    [Show full text]
  • Soma and Haoma: Ayahuasca Analogues from the Late Bronze Age
    ORIGINAL ARTICLE Journal of Psychedelic Studies 3(2), pp. 104–116 (2019) DOI: 10.1556/2054.2019.013 First published online July 25, 2019 Soma and Haoma: Ayahuasca analogues from the Late Bronze Age MATTHEW CLARK* School of Oriental and African Studies (SOAS), Department of Languages, Cultures and Linguistics, University of London, London, UK (Received: October 19, 2018; accepted: March 14, 2019) In this article, the origins of the cult of the ritual drink known as soma/haoma are explored. Various shortcomings of the main botanical candidates that have so far been proposed for this so-called “nectar of immortality” are assessed. Attention is brought to a variety of plants identified as soma/haoma in ancient Asian literature. Some of these plants are included in complex formulas and are sources of dimethyl tryptamine, monoamine oxidase inhibitors, and other psychedelic substances. It is suggested that through trial and error the same kinds of formulas that are used to make ayahuasca in South America were developed in antiquity in Central Asia and that the knowledge of the psychoactive properties of certain plants spreads through migrants from Central Asia to Persia and India. This article summarizes the main arguments for the botanical identity of soma/haoma, which is presented in my book, The Tawny One: Soma, Haoma and Ayahuasca (Muswell Hill Press, London/New York). However, in this article, all the topics dealt with in that publication, such as the possible ingredients of the potion used in Greek mystery rites, an extensive discussion of cannabis, or criteria that we might use to demarcate non-ordinary states of consciousness, have not been elaborated.
    [Show full text]
  • Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion and Pharmacokinetics
    TESI DOCTORAL HUMAN PHARMACOLOGY OF AYAHUASCA JORDI RIBA Barcelona, 2003 Director de la Tesi: DR. MANEL JOSEP BARBANOJ RODRÍGUEZ A la Núria, el Marc i l’Emma. No pasaremos en silencio una de las cosas que á nuestro modo de ver llamará la atención... toman un bejuco llamado Ayahuasca (bejuco de muerto ó almas) del cual hacen un lijero cocimiento...esta bebida es narcótica, como debe suponerse, i á pocos momentos empieza a producir los mas raros fenómenos...Yo, por mí, sé decir que cuando he tomado el Ayahuasca he sentido rodeos de cabeza, luego un viaje aéreo en el que recuerdo percibia las prespectivas mas deliciosas, grandes ciudades, elevadas torres, hermosos parques i otros objetos bellísimos; luego me figuraba abandonado en un bosque i acometido de algunas fieras, de las que me defendia; en seguida tenia sensación fuerte de sueño del cual recordaba con dolor i pesadez de cabeza, i algunas veces mal estar general. Manuel Villavicencio Geografía de la República del Ecuador (1858) Das, was den Indianer den “Aya-huasca-Trank” lieben macht, sind, abgesehen von den Traumgesichten, die auf sein persönliches Glück Bezug habenden Bilder, die sein inneres Auge während des narkotischen Zustandes schaut. Louis Lewin Phantastica (1927) Agraïments La present tesi doctoral constitueix la fase final d’una idea nascuda ara fa gairebé nou anys. El fet que aquest treball sobre la farmacologia humana de l’ayahuasca hagi estat una realitat es deu fonamentalment al suport constant del seu director, el Manel Barbanoj. Voldria expressar-li la meva gratitud pel seu recolzament entusiàstic d’aquest projecte, molt allunyat, per la natura del fàrmac objecte d’estudi, dels que fins al moment s’havien dut a terme a l’Àrea d’Investigació Farmacològica de l’Hospital de Sant Pau.
    [Show full text]
  • (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact
    pharmaceuticals Review Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact Andreia Machado Brito-da-Costa 1 , Diana Dias-da-Silva 1,2,* , Nelson G. M. Gomes 1,3 , Ricardo Jorge Dinis-Oliveira 1,2,4,* and Áurea Madureira-Carvalho 1,3 1 Department of Sciences, IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal; [email protected] (A.M.B.-d.-C.); ngomes@ff.up.pt (N.G.M.G.); [email protected] (Á.M.-C.) 2 UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 3 LAQV-REQUIMTE, Laboratory of Pharmacognosy, Department of Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 4 Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal * Correspondence: [email protected] (D.D.-d.-S.); [email protected] (R.J.D.-O.); Tel.: +351-224-157-216 (R.J.D.-O.) Received: 21 September 2020; Accepted: 20 October 2020; Published: 23 October 2020 Abstract: Ayahuasca is a hallucinogenic botanical beverage originally used by indigenous Amazonian tribes in religious ceremonies and therapeutic practices. While ethnobotanical surveys still indicate its spiritual and medicinal uses, consumption of ayahuasca has been progressively related with a recreational purpose, particularly in Western societies. The ayahuasca aqueous concoction is typically prepared from the leaves of the N,N-dimethyltryptamine (DMT)-containing Psychotria viridis, and the stem and bark of Banisteriopsis caapi, the plant source of harmala alkaloids.
    [Show full text]
  • Effect of Harmine on Nicotine‑Induced Kidney Dysfunction in Male Mice
    [Downloaded free from http://www.ijpvmjournal.net on Tuesday, June 25, 2019, IP: 94.199.136.196] Original Article Effect of Harmine on Nicotine‑Induced Kidney Dysfunction in Male Mice Abstract Mohammad Reza Background: The nicotine content of cigarettes plays a key role in the pathogenesis of kidney Salahshoor, disease. Harmine is a harmal‑derived alkaloid with antioxidant properties. This study was Shiva Roshankhah, designed to evaluate the effects of harmine against nicotine‑induced damage to the kidneys of mice. Methods: In this study, 64 male mice were randomly assigned to eight groups: saline and Vahid Motavalian, nicotine‑treated groups (2.5 mg/kg), harmine groups (5, 10, and 15 mg/kg), and nicotine (2.5 mg/ Cyrus Jalili kg) + harmine‑treated groups (5, 10, and 15 mg/kg). Treatments were administered intraperitoneally Department of Anatomical daily for 28 days. The weights of the mice and their kidneys, kidney index, glomeruli characteristics, Sciences, Medical School, thiobarbituric acid reactive species, antioxidant capacity, kidney function indicators, and serum Kermanshah University of nitrite oxide levels were investigated. Results: Nicotine administration significantly improved kidney Medical Sciences, Daneshgah Ave., Taghbostan, malondialdehyde (MDA) level, blood urea nitrogen (BUN), creatinine, and nitrite oxide levels and Kermanshah, Iran decreased glomeruli number and tissue ferric reducing/antioxidant power (FRAP) level compared to the saline group (P < 0.05). The harmine and harmine + nicotine treatments at all doses significantly reduced BUN, kidney MDA level, creatinine, glomerular diameter, and nitrite oxide levels and increased the glomeruli number and tissue FRAP level compared to the nicotine group (P < 0.05). Conclusions: It seems that harmine administration improved kidney injury induced by nicotine in mice.
    [Show full text]
  • Harmine and Imipramine Promote Antioxidant Activities in Prefrontal Cortex and Hippocampus
    RESEArcH PAPER RESEArcH PAPER Oxidative Medicine and Cellular Longevity 3:5, 325-331; September/October 2010; © 2010 Landes Bioscience Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus Gislaine Z. Réus,1 Roberto B. Stringari,1 Bruna de Souza,2 Fabrícia Petronilho,2 Felipe Dal-Pizzol,2 Jaime E. Hallak,3 Antônio W. Zuardi,3 José A. Crippa3 and João Quevedo1,* 1Laboratório de Neurociências; and 2Laboratório de Fisiopatologia Experimental; Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM); Programa de Pós-Graduação em Ciências da Saúde; Unidade Acadêmica de Ciências da Saúde; Universidade do Extremo Sul Catarinense; Criciúma, SC Brazil; 3Departamento de Neurociências e Ciências do Comportamento; Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM); Faculdade de Medicina de Ribeirão Preto; Universidade de São Paulo; Ribeirão Preto, SP Brazil Key words: harmine, imipramine, reactive oxygen species, antioxidants activity, depression A growing body of evidence has suggested that reactive oxygen species (ROS) may play an important role in the physiopathology of depression. Evidence has pointed to the β-carboline harmine as a potential therapeutic target for the treatment of depression. The present study we evaluated the effects of acute and chronic administration of harmine (5, 10 and 15 mg/kg) and imipramine (10, 20 and 30 mg/kg) or saline in lipid and protein oxidation levels and superoxide dismutase (SOD) and catalase (CAT) activities in rat prefrontal cortex and hippocampus. Acute and chronic treatments with imipramine and harmine reduced lipid and protein oxidation, compared to control group in prefrontal cortex and hippocampus. The SOD and CAT activities increased with acute and chronic treatments with imipramine and harmine, compared to control group in prefrontal cortex and hippocampus.
    [Show full text]
  • Ayahuasca Characterization, Metabolism in Humans, And
    Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 2012 Ayahuasca characterization, metabolism in humans, and relevance to endogenous N,N- dimethyltryptamines Ethan Hamilton McIlhenny Louisiana State University and Agricultural and Mechanical College, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Part of the Medicine and Health Sciences Commons Recommended Citation McIlhenny, Ethan Hamilton, "Ayahuasca characterization, metabolism in humans, and relevance to endogenous N,N- dimethyltryptamines" (2012). LSU Doctoral Dissertations. 2049. https://digitalcommons.lsu.edu/gradschool_dissertations/2049 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. AYAHUASCA CHARACTERIZATION, METABOLISM IN HUMANS, AND RELEVANCE TO ENDOGENOUS N,N-DIMETHYLTRYPTAMINES A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and School of Veterinary Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Interdepartmental Program in Veterinary Medical Sciences through the Department of Comparative Biomedical Sciences by Ethan Hamilton McIlhenny B.A., Skidmore College, 2006 M.S., Tulane University, 2008 August 2012 Acknowledgments Infinite thanks, appreciation, and gratitude to my mother Bonnie, father Chaffe, brother Matthew, grandmothers Virginia and Beverly, and to all my extended family, friends, and loved ones. Without your support and the visionary guidance of my friend and advisor Dr. Steven Barker, none of this work would have been possible. Special thanks to Dr.
    [Show full text]
  • Antidepressant & Psychedelic Drug Interaction Chart
    Copyright Psychedelic School 8/2020 Antidepressant & Psychedelic Drug Interaction Chart This chart is not intended to be used to make medical decisions and is for informational purposes only. It was constructed using data whenever possible, although extrapolation from known information was also used to inform risk. Any decision to start, stop, or taper medication and/or use psychedelic drugs should be made in conjunction with your healthcare provider(s). It is recommended to not perform any illicit activity. This chart the intellectual property of psychedelic school and is for personal use only. Please do not copy or distribute this chart. Antidepressant Phenethylamines Tryptamines MAOI-containing Ketamine Ibogaine -MDMA, mescaline -Psilocybin, LSD -Ayahuasca, Syrian Rue SSRIs Taper & discontinue at least 2 Consider taper & Taper & discontinue at least 2 Has been studied and Taper & discontinue at · Paroxetine (Paxil) weeks prior (all except discontinuation at least 2 weeks weeks prior (all except found effective both with least 2 weeks prior (all · Sertraline (Zoloft) fluoxetine) or 6 weeks prior prior (all except fluoxetine) or 6 fluoxetine) or 6 weeks prior and without concurrent except fluoxetine) or 6 · Citalopram (Celexa) (fluoxetine only) due to loss of weeks prior (fluoxetine only) (fluoxetine only) due to use of antidepressants weeks prior (fluoxetine · Escitalopram (Lexapro) psychedelic effect due to potential loss of potential risk of serotonin only) due to risk of · Fluxoetine (Prozac) psychedelic effect syndrome additive QTc interval · Fluvoxamine (Luvox) MDMA is unable to cause Recommended prolongation, release of serotonin when the Chronic antidepressant use may Life threatening toxicities can to be used in conjunction arrhythmias, or SPARI serotonin reuptake pump is result in down-regulation of occur with these with oral antidepressants cardiotoxicity · Vibryyd (Vilazodone) blocked.
    [Show full text]
  • Current Neuropharmacology, 2019, 17, 108-128 REVIEW ARTICLE
    108 Send Orders for Reprints to [email protected] Current Neuropharmacology, 2019, 17, 108-128 REVIEW ARTICLE ISSN: 1570-159X eISSN: 1875-6190 Ayahuasca: Psychological and Physiologic Effects, Impact Factor: Pharmacology and Potential Uses in Addiction and 4.068 Mental Illness BENTHAM SCIENCE Jonathan Hamilla, Jaime Hallaka,b, Serdar M. Dursuna and Glen Bakera,* aDepartment of Psychiatry (Neurochemical Research Unit) and Neuroscience & Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada; bDepartment of Neurosciences and Behavior and National Institute of Science and Technology (Translational Medicine), Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil Abstract: Background: Ayahuasca, a traditional Amazonian decoction with psychoactive proper- ties, is made from bark of the Banisteriopsis caapi vine (containing beta-carboline alkaloids) and leaves of the Psychotria viridis bush (supplying the hallucinogen N,N-dimethyltryptamine, DMT). Originally used by indigenous shamans for the purposes of spirit communication, magical experi- ences, healing, and religious rituals across several South American countries, ayahuasca has been incorporated into folk medicine and spiritual healing, and several Brazilian churches use it routinely to foster a spiritual experience. More recently, it is being used in Europe and North America, not only for religious or healing reasons, but also for recreation. Objective: To review ayahuasca’s behavioral effects, possible adverse effects, proposed mechanisms A R T I C L E H I S T O R Y of action and potential clinical uses in mental illness. Received: July 26, 2017 Method: We searched Medline, in English, using the terms ayahuasca, dimethyltryptamine, Banis- Revised: November 07, 2017 teriopsis caapi, and Psychotria viridis and reviewed the relevant publications.
    [Show full text]